Is It Too Late to Buy Moderna Stock After Its 127% Surge?

Moderna surged ~127% in weeks after announcing positive top-line Phase 3 INTerpath-001 results (Intismeran Autogene + Merck’s Keytruda) for melanoma, but the article flags that the move may have been amplified by a short squeeze (initially up as much as ~175%). Despite the promising oncology pivot, commercialization is expected to take years, with 2026 revenue estimated at ~$2.1B versus a ~$60B market cap and forecast FY losses of ~$8.55/share, implying expectations are already heavily priced in. The stock could pull back further as excitement cools, so the piece suggests waiting for weakness before buying.

Analysis

This is a classic duration mismatch: the market is paying today for a multi-year oncology platform option that may not convert into meaningful revenue until well into the next cycle. The move looks partially mechanical — short interest, narrative momentum, and a rerating of “what if” value — rather than a clean revaluation of near-term cash flow. At this size, MRNA is no longer being priced like a single-asset vaccine story; it is being priced as if success in one setting meaningfully de-risks an entire oncology franchise, which is too aggressive this early.

The cleaner beneficiary is MRK, but mostly as a low-volatility way to own incremental Keytruda lifecycle extension, not as a direct earnings step-up. If the combo works, Merck preserves share in a major oncology backbone and can potentially extend duration of its franchise; if it disappoints, downside is limited because the stock is not being driven by this program. That asymmetry makes MRK a better way to express cautious upside in the theme than chasing MRNA after a squeeze-like re-rating.

Contrarian view: consensus is underestimating how much of the recent move can mean-revert once probability-weighted NPV models catch up with the fact that commercialization is still years away. The biggest risk to a bearish call is follow-on data that broadens applicability or materially shortens the regulatory path; absent that, the stock can easily give back 15-25% as event premium fades. A second-order risk is competitive validation: if this works, BNTX and other mRNA names gain platform credibility, but that also dilutes any implied first-mover moat for MRNA itself.

Key Decisions for Investors

• Fade strength in MRNA with a 1-3 month horizon: buy put spreads or short on rallies into the recent post-news range; target a 15-25% retracement if no new catalyst emerges, with a hard stop above the recent spike high.
• Pair trade: long MRK / short MRNA for a 2-4 month view. MRK gets a cleaner, lower-risk optionality premium, while MRNA remains most exposed to valuation compression if the market re-centers on cash burn and years-to-monetization.
• If seeking a broader hedge on biotech sentiment, consider a small short XBI against a long MRK or healthcare basket position; MRNA-driven enthusiasm often bleeds into the high-beta biotech complex before fundamentals catch up.
• Do not add to MRNA until there is either a meaningful pullback or a new de-risking event (additional tumor readout, safety detail, or regulatory guidance) that advances approval timing; absent that, the setup is more trade than investment.